MARKET

AIM

AIM

AIM ImmunoTech Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

2.050
-0.040
-1.91%
After Hours: 2.070 +0.02 +0.98% 17:37 03/05 EST
OPEN
2.040
PREV CLOSE
2.090
HIGH
2.090
LOW
1.930
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
7.11
52 WEEK LOW
1.600
MARKET CAP
83.41M
P/E (TTM)
-4.6171
1D
5D
1M
3M
1Y
5Y
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.
GlobeNewswire · 1d ago
Radar Altimeters Market Growth 2021 Industry Share and Size, Movements by Key Findings, COVID-19 Impact, Latest Trend Analysis, Progression Status and Revenue Expectation to 2027 Research Report
Mar 03, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Radar Altimeters Market”...
The Express Wire · 2d ago
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
Benzinga · 02/24 18:57
DJ AIM ImmunoTech Shares Rise 13% After Ampligen Approved as Orphan Product
Dow Jones · 02/24 15:56
BRIEF-AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation By The European Medicines Agency For Ampligen To Treat Pancreatic Cancer
reuters.com · 02/24 14:59
AIM Immunotech shares jump after subsidiary nabs Orphan Medicinal Product status from EC
AIM ImmunoTech (AIM) company NV Hemispherx Biopharma Europe, has received formal notification from the European Commission ((EC)) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for
Seekingalpha · 02/24 14:29
DJ AIM ImmunoTech's Ampligen Gets Orphan Medicinal Product Application Approved
Dow Jones · 02/24 14:26
AIM ImmunoTechs Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer
Prof. Casper van Eijck, surgeon and a global leading expert in pancreatic cancer Prof. Casper van Eijck, surgeon and a global leading expert in pancreatic cancer Kazem Kazempour, Ph.D., CEO and President of Amarex Clinical Research, LLC Kazem Kazempour, Ph...
GlobeNewswire · 02/24 14:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIM. Analyze the recent business situations of AIM ImmunoTech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AIM stock price target is 6.33 with a high estimate of 7.50 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 93.54K
% Owned: 0.23%
Shares Outstanding: 40.69M
TypeInstitutionsShares
Increased
6
31
New
4
70.90K
Decreased
2
2.90K
Sold Out
7
13.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
William Mitchell
President/Chief Executive Officer/Vice Chairman/General Counsel/Secretary/Director
Thomas Equels
Chief Financial Officer
Ellen Lintal
Chief Operating Officer/General Counsel/Secretary
Peter Rodino
Senior Vice President
Wayne Springate
Chief Scientific Officer
David Strayer
Director
Stewart Appelrouth
No Data
About AIM
AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Webull offers kinds of AIM ImmunoTech Inc stock information, including AMEX:AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIM stock methods without spending real money on the virtual paper trading platform.